博客
Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target
AI for Longevity and Prosperity: Prosperity7 Leads Insilico's $35 Million Round D2 for $95 Million Total Raise
利用英矽智能的人工智能平台, 研究团队发现治疗ALS新希望
聚焦"合成致死"策略，英矽智能发现靶向USP1的临床前候选药物，用于多种抗肿瘤疗法开发
人工智能预测的双重靶点
Bridging Biology, Chemistry and Medicine in Drug Discovery and Development with End-to-End Artificial Intelligence: AI-discovered Novel Antifibrotic Drug Goes First-in-Human
Insilico Medicine Initiates First-in-Human Study of AI-discovered Drug
Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine
Insilico discovered a Novel disease mechanism, identified a Novel target, and designed a Novel molecule validated in preclinical experiments
Insilico Medicine to present Chemistry42 and the end-to-end drug discovery case study at NVIDIA GTC 2021
We are very happy to be presenting our approach to generative chemistry and the Chemistry42 platform at the NVIDIA GTC 2021 and the application of this platform which enabled the nomination of a pre-clinical candidate for a novel target for idiopathic pulmonary fibrosis (IPF) in under 18 months.
A breakthrough milestone in AI-powered drug discovery reached linking biology and chemistry with AI
AI-generated novel molecule for a novel target discovered with AI demonstrated efficacy in a broad therapeutic area and reached preclinical candidate stage in Idiopathic Pulmonary Fibrosis (IPF)
© 2022 Insilico Medicine
HONG KONG
Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong
NEW YORK
345 Park Avenue South,
2nd Floor Suite 006 New York,
NY 10010
2nd Floor Suite 006 New York,
NY 10010
MONTREAL
1250 Rene-Levesque West,
Suite 3710, Montreal, Quebec,
Canada H3B 4W8
Suite 3710, Montreal, Quebec,
Canada H3B 4W8
Subscribe to our news